Loading…
← CockpitCompetitor Analysis › 0126Z0.KS Samsung Epis Holdings Co., Ltd.Open in the cockpit ↗

Samsung Epis Holdings Co., Ltd.0126Z0.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Holding company for Samsung Bioepis, which develops and sells biosimilar drugs worldwide.

≈ A holding company over a Sandoz-style biosimilar makerMomentum strong 67
Mkt cap
$6.49B
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$12.1M
20-day average traded
Fwd P/E
23.8×
forward earnings
ROIC−WACC
-3.7 pp
WACC 5.8%
Hurdle
n/a
no reverse DCF
Next earnings
75 days
1 Feb 2027
Close · KRW₩362,500
1D+0.1%
1W+2.4%
1M+10.2%
3M-16.4%
6M-31.2%
YTD-51.2%
1Yn/a
ATR %5.3%
52w lowhigh53.1% off high

What Samsung Epis does

Holding company for Samsung Bioepis, which develops and sells biosimilar drugs worldwide.

Holds Samsung Bioepis, which sells biosimilars, near-copies of biologic drugs whose patents have expired, mostly through commercial partners in the US and Europe that handle sales. Bioepis is the main earner. Epis was split out as a holding company from Samsung Biologics in 2025.

In one line: A holding company over a Sandoz-style biosimilar maker.

Products and services

  • Samsung Bioepis (biosimilars)
  • Epis NexLab

Customers

  • Hospitals/health systems (US, Europe)

Where it sits in the supply chain

  • Biopharmaceuticals
  • Biosimilar holding company
  • Biosimilar development…

What could go right

  • Biosimilar share gains in Europe/US
  • New launches (e.g., aflibercept biosimilar)

What could go wrong

  • Biosimilar price erosion
  • Patent litigation risk

Moat: narrow (regulatory licence, process know-how). Biosimilar approvals and manufacturing scale-up are costly barriers for new entrants.

Headquarters: Incheon, South Korea · Founded: 2025 · Employees: 9

Named competitors

Samsung Epis at a glance

Size Samsung Epis (0126Z0.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $6.49B, the 64th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩362,500 on 18 Nov 2026.

Performance Over six months the shares fell 31.2%, against -4.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth The operating margin is 12.4% (peer median 15.8%).

Valuation It trades at 23.8× forward earnings against a peer median of 21.9× (8th cheapest of 15).

Capital Return on invested capital runs 3.7 points below its cost of capital (5.8% WACC).

Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 960126Z0.KS 71
Six months, rebased to 100: Samsung Epis against the median of its 20 peers (local-currency closes).

Samsung Epis financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025
Revenue₩1.54T₩252B
Revenue growth——
Gross profitn/a₩88.6B
EBITDAn/a₩5.34B
Net income₩250B-₩31.4B
Free cash flown/a-₩110B
Capital expendituren/a₩40.0B
Total debt₩607B₩378B

Quarterly statements and history in the cockpit →

Samsung Epis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-40%-20%0%+20%ORKABLTE000999BIOCONALKEM000963688331MIRMSUPN9926LGNDBANB6821IBRXCYTKGLANDCORT0126Z0.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Samsung Epis is the large dot.

Samsung Epis competitors and peer comparison

Head to head with its named competitors (0126Z0.KS vs SDZ.SW vs 068270.KS vs VTRS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Samsung Epis 0126Z0.KS$6.49B-31%n/a12%23.8×n/a
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%
Celltrion 068270.KS$34.9B+12%+40%32%33.9×10.6%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%

How Samsung Epis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Samsung Epis against its 20 peers (data as of 18 Nov 2026)
Measure0126Z0.KSPeer medianRank in peer set
1-month return+10.2%-2.1%3rd highest of 21
6-month return-31.2%-4.5%4th lowest of 20
Distance from 52-week high-53.1%-20.5%2nd lowest of 21
Operating margin12.4%15.8%8th lowest of 19
Forward P/E23.8×21.9×8th cheapest of 15
ROIC minus cost of capital-3.7 pp+2.2 pp7th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
RemeGen 688331.SSChina$6.28B-24%+272%61%10.8×1.1%+303.3%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%

Questions

Who are Samsung Epis's main competitors?
Named competitors: Sandoz (SDZ.SW), Celltrion (068270.KS), Viatris (VTRS). The cockpit's measured peer set (industry) also includes Oruka Therapeutics (ORKA), Apotex Health (APTX.TO), Belite Bio, Inc. ADR (BLTE), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Biocon (BIOCON.NS), Alkem Laboratories (ALKEM.NS).
Is Samsung Epis expensive compared with its peers?
On forward p/e it trades at 23.8× against a peer median of 21.9×, 8th cheapest of 15 in its peer set.
How has Samsung Epis stock performed?
Over six months to 18 Nov 2026 the shares returned -31.2% against -4.5% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.